Robert Manges, MD
Hematology & Oncology · Fort Wayne, INNPI 1508835174
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,994 of the $31,169 with a category attached, or 67.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.4%. Reporting peaked in 2019 at $10,904 and has fallen 82.7% since, to $1,890 in 2025.
Across 790 payments — averaging $39.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- AstraZeneca$4K
- Johnson & Johnson$2K
- Rigel Pharmaceuticals, Inc.$2K
- Gilead$1K
- Pharmacyclics LLC, An Abbvie Company$916
- plus $14K from 54 others
Across 42 payments — averaging $5686.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$94K
- Astrazeneca UK Limited$87K
- Bristol Myers Squibb$37K
- Merck$8K
- Genentech, Inc.$8K
- E.r. Squibb & Sons, L.L.C.$5K
What the payments were for
- Consulting fees$7,84025%
- Speaking & faculty fees$1,5385%
- Travel & lodging$1871%
- Food & beverage$20,99467%
- Education$6102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kyprolis$5,337
- LYNPARZA$1,913
- Tavalisse$1,534
- IMFINZI$863
- RYBREVANT$552
- DARZALEX$482
- DOPTELET$375
- TECVAYLI$375
- IMBRUVICA$340
- CALQUENCE$254
- INJECTAFER$249
- Nplate$242
- JAKAFI$240
- PYRUKYND$233
- INQOVI$228
- CARVYKTI$223
- FOUNDATIONONE$222
- FOUNDATIONONE HEME$222
- FOUNDATIONONE CDX$222
- FOUNDATIONFOCUS$222
How this compares
$31,169 in reported general payments places this provider in the 80th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 99 | $1,603,806 |
| AyvakitAvapritinib | 24 | $1,504,820 |
| ImbruvicaIbrutinib | 73 | $1,223,816 |
| VenclextaVenetoclax | 73 | $997,031 |
| PomalystPomalidomide | 32 | $742,683 |
| BosulifBosutinib | 45 | $737,292 |
| CalquenceAcalabrutinib Maleate | 45 | $655,028 |
| BrukinsaZanubrutinib | 46 | $595,215 |
| TibsovoIvosidenib | 16 | $531,341 |
| Lenalidomide | 41 | $516,615 |
| JakafiRuxolitinib Phosphate | 27 | $380,058 |
| XpovioSelinexor | 13 | $378,516 |
| AlunbrigBrigatinib | 17 | $332,236 |
| TasignaNilotinib Hcl | 20 | $301,424 |
| RevlimidLenalidomide | 16 | $295,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $4,090 | $2,258,834144 claims |
| Blueprint Medicines CorporationAyvakit | $225 | $1,504,82024 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $916 | $1,223,81673 claims |
| PfizerBosulif, Eliquis, Ibrance | $478 | $1,105,756240 claims |
| AbbVieVenclexta | $464 | $997,03173 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $902 | $981,08245 claims |
| Beigene USA, Inc.Brukinsa | $381 | $595,21546 claims |
| NovartisTasigna, Scemblix | $353 | $559,62432 claims |
| Incyte CorporationJakafi | $636 | $380,05827 claims |
| Karyopharm Therapeutics Inc.Xpovio | $440 | $378,51613 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig | $453 | $332,23617 claims |
| Bristol Myers SquibbRevlimid | $241 | $295,50416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Fort Wayne
- Ahad SadiqFort Wayne$430K
- Zhentao ZhangFort Wayne$167K
- Sreenivasa NattamFort Wayne$120K
- Praveen KolliparaFort Wayne$88K
- Dolly Quispe LeveauFort Wayne$74K
- Matthew CarrFort Wayne$51K
- Shalini ChitneniFort Wayne$46K
- Ryan GonzalesFort Wayne$38K
- Michael TooleFort Wayne$27K
- Melanie ClarkFort Wayne$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.